Keykavous Parang
Keykavous Parang
Associate Dean of Research, Innovation, and Global Affairs, Professor, Chapman University, and
Verified email at - Homepage
Cited by
Cited by
Mechanism-based design of a protein kinase inhibitor
K Parang, JH Till, AJ Ablooglu, RA Kohanski, SR Hubbard, PA Cole
Nature structural biology 8 (1), 37-41, 2001
Self-assembly of peptides to nanostructures
D Mandal, AN Shirazi, K Parang
Organic & biomolecular chemistry 12 (22), 3544-3561, 2014
Novel Approaches for Designing 5'-O-Ester Prodrugs of 3'-Azido-2'3'-Dideoxythymidine (AZT)
K Parang, LI Wiebe, EE Knaus
Current medicinal chemistry 7 (10), 995-1039, 2000
Protein pyrophosphorylation by inositol pyrophosphates is a posttranslational event
R Bhandari, A Saiardi, Y Ahmadibeni, AM Snowman, AC Resnick, ...
Proceedings of the National Academy of Sciences 104 (39), 15305-15310, 2007
Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease
T Force, K Kuida, M Namchuk, K Parang, JM Kyriakis
Circulation 109 (10), 1196-1205, 2004
Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity
BJ Fowler, BD Gelfand, Y Kim, N Kerur, V Tarallo, Y Hirano, S Amarnath, ...
Science 346 (6212), 1000-1003, 2014
Cell‐penetrating homochiral cyclic peptides as nuclear‐targeting molecular transporters
D Mandal, A Nasrolahi Shirazi, K Parang
Angewandte Chemie International Edition 50 (41), 9633-9637, 2011
Impairment of TrkB-PSD-95 signaling in Angelman syndrome
C Cao, MS Rioult-Pedotti, P Migani, JY Crystal, R Tiwari, K Parang, ...
PLoS Biol 11 (2), e1001478, 2013
Current targets for anticancer drug discovery
NH Nam, K Parang
Current drug targets 4 (2), 159-179, 2003
Designing bisubstrate analog inhibitors for protein kinases
K Parang, PA Cole
Pharmacology & therapeutics 93 (2-3), 145-157, 2002
Synthesis of 3-phenylpyrazolopyrimidine-1, 2, 3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities
A Kumar, I Ahmad, BS Chhikara, R Tiwari, D Mandal, K Parang
Bioorganic & medicinal chemistry letters 21 (5), 1342-1346, 2011
Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase
S Lee, X Lin, NH Nam, K Parang, G Sun
Proceedings of the National Academy of Sciences 100 (25), 14707-14712, 2003
Design and biological evaluation of cell-penetrating peptide–doxorubicin conjugates as prodrugs
A Nasrolahi Shirazi, R Tiwari, BS Chhikara, D Mandal, K Parang
Molecular pharmaceutics 10 (2), 488-499, 2013
Development of cytarabine prodrugs and delivery systems for leukemia treatment
BS Chhikara, K Parang
Expert opinion on drug delivery 7 (12), 1399-1414, 2010
Design strategies for protein kinase inhibitors.
K Parang, G Sun
Current opinion in drug discovery & development 7 (5), 617-629, 2004
Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding
NH Nam, G Ye, G Sun, K Parang
Journal of medicinal chemistry 47 (12), 3131-3141, 2004
3-Substitued indoles: one-pot synthesis and evaluation of anticancer and Src kinase inhibitory activities
VK Rao, BS Chhikara, AN Shirazi, R Tiwari, K Parang, A Kumar
Bioorganic & medicinal chemistry letters 21 (12), 3511-3514, 2011
A review (research and patents) on jasmonic acid and its derivatives
A Ghasemi Pirbalouti, SE Sajjadi, K Parang
Archiv der Pharmazie 347 (4), 229-239, 2014
Fatty acyl amide derivatives of doxorubicin: Synthesis and in vitro anticancer activities
BS Chhikara, NS Jean, D Mandal, A Kumar, K Parang
European journal of medicinal chemistry 46 (6), 2037-2042, 2011
Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate
BS Chhikara, D Mandal, K Parang
Journal of medicinal chemistry 55 (4), 1500-1510, 2012
The system can't perform the operation now. Try again later.
Articles 1–20